2022-502584-38-00已完成3 期
A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study)
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 377
- 试验地点
- 27
- 主要终点
- PFS as assessed by independent review committee (IRC) defined as the time from randomization to the first occurrence of any of the following events: death from any cause, disease progression (PD), primary treatment failure before achieving a complete response (CR) or any radiological or clinical relapse after achieving a CR
研究概览
简要总结
To demonstrate improvement in PFS evaluated by an independent review committee (IRC) with xevinapant-cetuximab-RT compared to placebo-cetuximab-RT
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Male or Female ≥ 18 years (or based on the country legal age limit for adults on day of signing the Informed Consent Form, ICF) and < 80 years
- •ECOG PS 0-1
- •Histologically confirmed diagnosis in previously untreated LA-SCCHN participant (Stage III, IVA or IVB according to the American Joint Committee on Cancer [AJCC]/TNM Staging System, 8th Ed.) of at least one of the following sites: oral cavity, hypopharynx and larynx. OPC participants are also eligible but their primary tumor must be: • HPV-negative (Stage III, IVA or IVB according to the American Joint Committee on Cancer [AJCC]/TNM Staging System, 8th Ed.) or • HPV-positive and smokers > 20 PY and must have according to the American Joint Committee on Cancer [AJCC]/TNM Staging System, 8th Ed: o T3 N1-3 o T4 and any N
- •Able to swallow liquids or have an adequately functioning feeding tube, gastrostomy or jejunostomy placed.
- •Patients must be ineligible to receive high-dose cisplatin defined as ≥ 200 mg/m² (projected total cumulative dose throughout the course of the RT). Ineligibility is defined as at least one of the following criteria: • eGFR < 60 mL/min /1.73 m² (using the CKD-EPI creatinine formula) • History of hearing loss, defined as either: i. Existing need of a hearing aid and/or ii. Clinically relevant hearing loss by clinical assessment including tinnitus ≥ Grade
- •Note: In case of doubt, an audiogram should be requested to guide the Investigator • Peripheral neuropathy ≥ Grade 2 • Cardiac function not compatible with hyperhydration • If > 70 years, unfit according to G8 questionnaire (Score ≤ 14)
- •Adequate hematologic, renal and hepatic function as indicated by (using CTCAE v5.0): • Absolute neutrophil count ≥ 1500 /mm3 • Platelets ≥ 100 000 /mm3 • Hemoglobin ≥ 9.0 g/dL (blood transfusions during Screening are not permitted) • White blood cells ≥ 3 000/mm3 • AST and ALT ≤ 3 × ULN • eGFR ≥ 30 mL/min /1.73 m² (using the CKD-EPI creatinine formula) • Total bilirubin ≤ 1.5 × ULN (up to 2.0 × ULN is allowed if the direct bilirubin level is normal, and the elevation is limited to indirect bilirubin)
- •The Investigator confirms that the participant agrees to use appropriate contraception and barriers methods, if applicable
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the inform consent form and this protocol
排除标准
- •Any condition, including any uncontrolled disease state other than SCCHN that in the Investigator’s opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
- •Symptomatic pulmonary disease requiring continuous or intermittent oxygen supply.
- •History of another malignancy within the last 3 years prior to randomization, with the exception of completely resected non-melanoma cell skin cancer outside the head and neck area or completely resected stage I breast cancer, or completely resected in-situ non-muscular invasive bladder, cervix and/or uterine carcinomas.
- •Non compensated or symptomatic liver cirrhosis (Child-Pugh score: B or C).
- •Metastatic disease (according to AJCC/TNM, 8th ed.).
- •Primary tumor of nasopharyngeal, paranasal sinuses, salivary, thyroid or parathyroid gland, skin or unknown primary site.
- •Known gastrointestinal disorder with clinically established malabsorption syndrome and major gastrointestinal surgery that may limit oral absorption
- •Documented weight loss of > 10% during the last 4 weeks prior to randomization (unless adequate measures are undertaken for nutritional support), OR plasmatic albumin < 3.0 g/dL. No albumin transfusions are allowed within 2 weeks before randomization.
- •Active gastrointestinal bleeding, or any other uncontrolled bleeding requiring more than 2 red blood cell transfusions or 4 units of packed red blood cells within 4 weeks prior to randomization.
- •Active uncontrolled inflammatory disease (including rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, severe extensive psoriasis, and other autoimmune diseases) requiring ongoing treatment with anti-TNF medication.
- •Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following
- •Hypertension uncontrolled by medication (i.e. systolic blood pressure > 150 mmHg and diastolic blood pressure > 90 mmHg).
结局指标
主要结局
PFS as assessed by independent review committee (IRC) defined as the time from randomization to the first occurrence of any of the following events: death from any cause, disease progression (PD), primary treatment failure before achieving a complete response (CR) or any radiological or clinical relapse after achieving a CR
PFS as assessed by independent review committee (IRC) defined as the time from randomization to the first occurrence of any of the following events: death from any cause, disease progression (PD), primary treatment failure before achieving a complete response (CR) or any radiological or clinical relapse after achieving a CR
次要结局
- OS, main secondary endpoint, defined as the time from date of randomization to the date of death. Patients last known to be alive will be censored at date of last contact.
- Progression-free survival by investigator assessment.
- Compliance will be reported: for radiotherapy (tumor dose, number of fractions, duration and major deviations), for xevinapant/placebo, cetuximab (number of cycles, dose, duration, dose intensity and relative dose intensity). Whatever the treatment, treatment interruption, reduction and discontinuation and their reasons will be reported
- Occurrence of adverse events (AEs) and treatment-related AEs.
研究者
Cordinating investigator
Scientific
Groupe Oncologie Radiotherapie Tete Cou
研究点 (27)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)Chronic CoughNCT04193176Merck Sharp & Dohme LLC376
进行中（未招募）
3 期
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer PatientsNSCLCNCT03866499Beta Pharma Shanghai369
已完成
3 期
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)Chronic CoughNCT04193202Merck Sharp & Dohme LLC419
招募中
3 期
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaChronic Primary Immune Thrombocytopenia (ITP)NCT06004856Beijing InnoCare Pharma Tech Co., Ltd.195
已完成
3 期
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder (ADHD)NCT03260205Shire199